View our case study to learn how Applied BioMath Assess™ can be used to evaluate the risk of on-target, off-tumor toxicities for CD3 bispecific T-cell engagers and to make an early prediction about therapeutic index and projections of effective and tolerable doses for T-cell engagers in solid tumors. Learn more at: https://lnkd.in/ePquuEfw #TCEs #tcellengagers #preclinicaldevelopent #clinicladevelopment #solidtumors
Applied BioMath’s Post
More Relevant Posts
-
Listen to an #audio version of a #pressrelease about "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma." https://lnkd.in/ejXEX-sb
-
How effective is bimekizumab in patients with #PsoriaticArthritis who do not yield an adequate response to tumor necrosis factor inhibitors? Our latest summary focuses on data from the BE VITAL open-label extension here: https://loom.ly/w4BwGMQ #PsoriaticArthritis #MedicalEducation #MedEd
-
-
Listen to an #audio version of a #pressrelease about "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma." https://lnkd.in/ejXEX-sb
Comparison of FDG-PET/CT and CT for Treatment Evaluation of Patients With Unresectable Mesothelioma
soundcloud.com
-
The utterly hard-to-treat metastatic #CRC : #MSS #pMMR #BRAF #V600E #livermets , given #nivolumab #immunotherapy #ICB #ICI #ICPI following #immunogenic short-course #oxaliplatin based chemo, resulting in durable #CR. The #METIMMOX study 🇳🇴 Figure (one of the BRAF-V600E MSS/pMMR-CRC cases) -- top: at baseline; bottom: at complete response (even the primary tumor!)
-
-
Advantages of scFv Antibodies: Versatility: Due to their small size, scFv antibodies can penetrate tissues more effectively, including solid tumors. This property makes them promising candidates for targeted therapies and diagnostic applications. https://lnkd.in/eXEFfAYV #scFvAntibodies #CancerResearch #TherapeuticAdvancements #TumorTreatment #PrecisionMedicine #ImmunoOncology #PhageDisplayLibrary #DrugDevelopment #BiomedicalResearch #CellularTargeting #AntibodyEngineering #BiotechDiscovery #MedicalBreakthroughs #AlphaLifetech
-
-
📢Curious about the latest news in drugs for rare tumors? 💊 Join us in Red Room 1 at #SIOPEurope2024 for a crucial session on accessing innovative treatments for very rare tumors. Explore insights provided by the ITCC and EXPeRT Groups. ✅
-
-
Advantages of scFv Antibodies: Versatility: Due to their small size, scFv antibodies can penetrate tissues more effectively, including solid tumors. This property makes them promising candidates for targeted therapies and diagnostic applications. https://lnkd.in/et_WVeFT #scFvAntibodies #CancerResearch #TherapeuticAdvancements #TumorTreatment #PrecisionMedicine #ImmunoOncology #PhageDisplayLibrary #DrugDevelopment #BiomedicalResearch #CellularTargeting #AntibodyEngineering #BiotechDiscovery #MedicalBreakthroughs #AlphaLifetech
-
-
#MARIPOSA 🧠CNS Metastases Detection: Serial head imaging in the trial allowed for more frequent detection of CNS metastases and robust assessment of treatment effects, making comparisons with studies not using head imaging irrelevant. 🩸Venous Thromboembolic Events: The amivantamab-lazertinib group had a higher incidence of venous thromboembolic events, mostly within the first four months, likely due to rapid tumor cell death. However, severe events and treatment discontinuation rates were low and similar between both groups. 🔬Blinded EGFR-TKI Evaluation: Blinded evaluation of osimertinib and lazertinib showed similar progression-free survival, confirming the efficacy of both drugs and the value of comparing lazertinib directly with osimertinib. https://lnkd.in/gHjPSgfj
-
-
Looking for reliable, fast insights into angiogenesis, tumor growth, or drug effects? Our CAM Assay Services are designed to help you push the boundaries of research with precision and speed. Reach out today and see how we can support your next breakthrough. #ChorioallantoicMembrane #CAMAssay #AngiogenesisTesting #TumorGrowthAnalysis #DrugEfficacyTesting #CancerResearch #InVivoModel #MetastasisStudy #WoundHealingAssay #ToxicityScreening #CellMigrationAssay #PreclinicalDrugTesting #BiotechResearch #TissueEngineering #VascularResearch #3DCellCulture #BiomedicalResearch #Tumorigenesis #EmbryoBasedAssays #HighThroughputScreening
-
-
A secondary analysis from MARIPOSA 1. In the MARIPOSA study, 89% of patients with analyzable ctDNA in the amivantamab-lazertinib and osimertinib arms had at least one high-risk feature at baseline. 2. Amivantamab-lazertinib significantly improved PFS compared to osimertinib in patients with TP53 co-mutations (HR 0.65; P = 0.003). 3. Amivantamab showed single-agent activity in patients with liver metastases, likely due to its MET activity associated with increased MET expression in the liver. 4. Patients without ctDNA clearance at C3D1 experienced the shortest PFS among all high-risk subgroups. In the MARIPOSA study, these patients had a median PFS of 9.1 months in the osimertinib arm compared to 16.5 months in the amivantamab-lazertinib arm (HR 0.49; P = 0.015). Ref: https://lnkd.in/ggwkqx-z
#MARIPOSA 🧠CNS Metastases Detection: Serial head imaging in the trial allowed for more frequent detection of CNS metastases and robust assessment of treatment effects, making comparisons with studies not using head imaging irrelevant. 🩸Venous Thromboembolic Events: The amivantamab-lazertinib group had a higher incidence of venous thromboembolic events, mostly within the first four months, likely due to rapid tumor cell death. However, severe events and treatment discontinuation rates were low and similar between both groups. 🔬Blinded EGFR-TKI Evaluation: Blinded evaluation of osimertinib and lazertinib showed similar progression-free survival, confirming the efficacy of both drugs and the value of comparing lazertinib directly with osimertinib. https://lnkd.in/gHjPSgfj
-
